Early use of tocilizumab in the prevention of adult respiratory failure in SARS-CoV-2 infections and the utilization of interleukin-6 levels in the management. https://doi.org/10.1002/jmv.26288 In this longitudinal observational study, 112 patients were evaluated from 2/1/2020 – 5/31/2020. TCZ was administered… Continue reading "(10 July 2020) Tocilizumab- early use reduced need of MV"
Serious adverse events with tocilizumab: pharmacovigilance as an aid to prioritize monitoring in COVID-19. https://bpspubs.onlinelibrary.wiley.com/doi/epdf/10.1111/bcp.14459 To characterize serious adverse events (AEs) with tocilizumab, authors queried the worldwide FDA Adverse Event Reporting System and perform disproportionality analysis, selecting only designated medical… Continue reading "(09 July 2020) Tocilizumab- non-negligible proportion of deaths due to life-threatening hepatic reactions"
Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial) https://www.medrxiv.org/content/10.1101/2020.07.07.20145979v1 This Pilot clinical trial was conducted on hospitalized adult patients with mild to moderate COVID-19 diagnosed according to WHO interim guidance. Sixteen Patients received a single dose of… Continue reading "(08 July 2020) Ivermectin- add on use to HCQ and AZT improved effectiveness"
Tocilizumab in patients with severe COVID‐19: A single‐center observational analysis https://doi.org/10.1002/jmv.26191 This is a retrospective single‐center analysis of the records of patients diagnosed with COVID‐19 who received tocilizumab. Outcomes, including clinical improvement, mortality and changes in oxygen‐support at 24, 48,… Continue reading "(07 July 2020) Tocilizumab- limited clinical improvement in patients"
Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series https://doi.org/10.1186/s13054-020-03078-z This is the first report on nafamostat mesylate treatment in combination with favipiravir against Covid-19. No interruption of antiviral treatment occurred due to… Continue reading "(06 July 2020) Favipiravir – low mortality rate with combination treatment of favipiravir and nafamostat mesylate"
Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19 https://doi.org/10.1016/j.ijid.2020.06.099 Of 2,541 patients, with a median total hospitalization time of 6 days (IQR: 4-10 days), median age was 64 years (IQR:53-76 years), 51% male, 56% African American, with… Continue reading "(06 July 2020) Hydroxychloroquine- use of hydroxychloroquine alone and in combination with azithromycin was associated with significant reduction in-hospital mortality"
Lopinavir/ritonavir is associated with pneumonia resolution in COVID-19 patients with influenza coinfection: a retrospective matched-pair cohort study https://doi.org/10.1002/jmv.26260 This is a retrospective study of 128 hospitalized patients with COVID-19 pneumonia. All patients were positive severe acute respiratory syndrome coronavirus 2… Continue reading "(05 July 2020) Lopinavir/Ritonavir- associated with faster pneumonia resolution within two weeks after symptom onset (37% vs 1%, P=0.001)"
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study https://ard.bmj.com/content/early/2020/07/03/annrheumdis-2020-218122 In an open-label study of sarilumab in severe COVID-19 pneumonia (PaO2/FiO2 <300 mm Hg) with hyperinflammation (elevated inflammatory markers and serum IL-6 levels), sarilumab… Continue reading "(04 July 2020) Sarilumab- At day 28, not significant difference between sarilumab and SoC"
Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis https://doi.org/10.1007/s11684-020-0800-y In a single-center, retrospective analysis of hospitalized adult COVID-19 patients in Wuhan, China, patients on anti-hypertensive treatment with or without ACEI/ARB… Continue reading "(04 July 2020) ACEi and ARB- no significant association between ACEI/ARB treatment and severe COVID-19 outcomes"
Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis https://doi.org/10.1002/jmv.26256 A total of 12 studies with 1052 patients were included in final review studies. Compared with control group, umifenovir is associated with higher negative… Continue reading "(03 July 2020) Umifenovir-no evidence to support the use of umifenovir for improving patient-important outcomes"
